ORGO Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
37.2M
-83.5%
225.6M
+49.5%
150.9M
+49.4%
101.0M
+16.5%
86.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
37.2M
-83.5%
225.6M
+49.5%
150.9M
+49.4%
101.0M
+16.5%
86.7M
Operating Expenses
106.1M
-34.6%
162.3M
+24.7%
130.1M
+14.6%
113.6M
+0.1%
113.4M
R&D
15.2M
+47.4%
10.3M
-22.2%
13.2M
+27.2%
10.4M
-2.3%
10.6M
SG&A
65.2M
-34.9%
100.2M
+25.6%
79.7M
+8.0%
73.8M
+1.8%
72.5M
Operating Income
-68891000
-208.9%
63.3M
+205.3%
20.7M
+264.8%
-12576000
+53.0%
-26746000
EBITDA
-59009000
-184.2%
70.1M
+164.3%
26.5M
+524.0%
-6255000
+60.6%
-15893000
Net Income
-53156000
-221.6%
43.7M
+102.6%
21.6M
+329.6%
-9392000
+50.2%
-18843000
EPS (Basic)
$-0.44
-257.1%
$0.28
+154.5%
$0.11
+210.0%
$-0.10
+41.2%
$-0.17
EPS (Diluted)
$-0.44
-269.2%
$0.26
+136.4%
$0.11
+210.0%
$-0.10
+41.2%
$-0.17
Shares (Diluted)
127.8M
-6.7%
137.0M
+4.7%
130.8M
+3.1%
126.9M
+0.4%
126.3M
Organogenesis (ORGO) โ€” Financials